Insights

Gathering insights about Rally…

Similar companies to Rally

Rally Tech Stack

Rally uses 8 technology products and services including Smartlook, Cloudflare CDN, Google Font API, and more. Explore Rally's tech stack below.

Smartlook
Analytics
Cloudflare CDN
Content Delivery Network
Google Font API
Font Scripts
React
Javascript Frameworks
Stripe
Payment Processing
Vercel
Platform As A Service
Python
Programming Languages
HeatMap
Web Analytics

Media & News

Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66th American Society of Hematology Annual Meeting
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced the presentation of two posters highlighting promising preclinical data for pipeline candidates RLYB212 and RLYB332 at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 7–10, 2024 in San Diego, California. “With our.
Dec 10, 2024 | www.businesswire.com
Rallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced results of new biomarker characterization analyses and data from the recently completed manufacturing process enhancements for RLYB116, the Company's innovative, once-weekly, small volume, subcutaneously injected C5 inhibitor in development for the treatment of pat.
Dec 02, 2024 | www.businesswire.com
Rallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced the publication of a manuscript titled, “Informing Pregnancy Dose via Target-Mediated Drug Disposition Modeling and Simulations for a Recombinant Human Monoclonal Antibody,” in a special pregnancy themed issue of Clinical Pharmacology and Therapeutics: Pharmacometr.
Nov 27, 2024 | www.businesswire.com
Rallybio to Present at the 2024 Evercore ISI HealthCONx Conference
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced that Stephen Uden, M.D., Chief Executive Officer of Rallybio, will participate in a fireside chat at the Evercore ISI HealthCONx Conference on Wednesday, December 4, 2024 at 12:30 p.m. ET in Coral Gables, FL. A live webcast of the fireside chat will be accessible t.
Nov 26, 2024 | www.businesswire.com
Rallybio to Provide Update on RLYB116 Program, an Innovative Subcutaneously Injected C5 Inhibitor
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced that the Company will host a webcast to provide a program update on RLYB116, its innovative, once-weekly, small volume, subcutaneously injected C5 inhibitor in development for the treatment of patients with complement-mediated diseases. The webcast will take place.
Nov 25, 2024 | www.businesswire.com
Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced the initiation of its Phase 2 clinical trial investigating RLYB212 in pregnant women at higher risk for HPA-1a alloimmunization and fetal and neonatal alloimmune thrombocytopenia (FNAIT). Screening is now underway to identify the first (sentinel) pregnant woman for.
Nov 21, 2024 | www.businesswire.com
Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the American Society of Human Genetics 2024 Annual Meeting
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, announced today that full data from an epidemiological analysis quantifying the proportion of women across diverse populations at higher risk of a fetal and neonatal alloimmune thrombocytopenia (FNAIT)-impacted pregnancy will be presented at the American Society of Human Genetics.
Sep 23, 2024 | www.businesswire.com

Rally's Email Address Formats

Rally uses at least 1 format(s):

Rally Email Formats	Example	Percentage
FLast@rally.io	JDoe@rally.io	50%
FLast@rally.io	JDoe@rally.io	50%

Frequently Asked Questions

Where is Rally's headquarters located?

Rally's main headquarters is located at San Francisco, California US. The company has employees across 5 continents, including North AmericaAsiaAfrica.

What is Rally's stock symbol?

Rally is a publicly traded company; the company's stock symbol is RLYB.

What is Rally's official website and social media links?

Rally's official website is rally.io and has social profiles on LinkedIn.

How much revenue does Rally generate?

As of September 2024, Rally's annual revenue reached $3.8M.

How many employees does Rally have currently?

As of September 2024, Rally has approximately 49 employees across 5 continents, including North AmericaAsiaAfrica. Key team members include Chief Executive Officer: R. C.Chief Financial Officer: J. T.Head Of Networks: A. R.. Explore Rally's employee directory with LeadIQ.

What industry does Rally belong to?

Rally operates in the Technology, Information and Internet industry.

What technology does Rally use?

Rally's tech stack includes SmartlookCloudflare CDNGoogle Font APIReactStripeVercelPythonHeatMap.

What is Rally's email format?

Rally's email format typically follows the pattern of . Find more Rally email formats with LeadIQ.

How much funding has Rally raised to date?

As of September 2024, Rally has raised $57M in funding. The last funding round occurred on Apr 28, 2021 for $57M.

When was Rally founded?

Rally was founded in 2020.

Rally

Technology, Information and InternetCalifornia, United States11-50 Employees

Our mission is to empower creators to build long-lasting successful online businesses.  Rally allows creators to form their own always-on digital economies centered on the value they create for their fans.  Powered by digital assets on the blockchain, Rally offers additive creator monetization through deeper fan engagement and rewards.

Company Overview

Headquarters: San Francisco, California US
Website: rally.io
Stock Symbol: RLYB
Founded: 2020
Employees: 11-50

Media & News

Funding & Financials

$57M
Rally has raised a total of $57M of funding over 2 rounds. Their latest funding round was raised on Apr 28, 2021 in the amount of $57M.
$10M
Rally's revenue is in the range of $10M

Funding & Financials

$57M
Rally has raised a total of $57M of funding over 2 rounds. Their latest funding round was raised on Apr 28, 2021 in the amount of $57M.
$10M
Rally's revenue is in the range of $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to Rally

Rational 360

Purple Strategies

Mercury

SKDK

Hamilton Place Strategies

Kivvit

BerlinRosen

Turnberry Solutions

Vrge Strategies

Rally Tech Stack

Media & News

Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66th American Society of Hematology Annual Meeting

Rallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025

Rallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women

Rallybio to Present at the 2024 Evercore ISI HealthCONx Conference

Rallybio to Provide Update on RLYB116 Program, an Innovative Subcutaneously Injected C5 Inhibitor

Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212

Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the American Society of Human Genetics 2024 Annual Meeting

Rally's Email Address Formats

Frequently Asked Questions

Where is Rally's headquarters located?

What is Rally's stock symbol?

What is Rally's official website and social media links?

How much revenue does Rally generate?

How many employees does Rally have currently?

What industry does Rally belong to?

What technology does Rally use?

What is Rally's email format?

How much funding has Rally raised to date?

When was Rally founded?

Rally

Company Overview

Media & News

Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66th American Society of Hematology Annual Meeting

Rallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025

Rallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?